JavaScript NENÍ povolen !

Článek
Článek online

FT
Medvik - BMČ

Je něco špatně v tomto záznamu ?

Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study

HE. White, M. Salmon, F. Albano, CSA. Andersen, S. Balabanov, G. Balatzenko, G. Barbany, JM. Cayuela, N. Cerveira, P. Cochaux, D. Colomer, D. Coriu, J. Diamond, C. Dietz, S. Dulucq, M. Engvall, GN. Franke, E. Gineikiene-Valentine, M. Gniot, MT....

Leukemia. 2022 ; 36 (7) : 1834-1842. [pub] 20220525

ISSN 1476-5551
Medvik
Zdroj

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz https://www.medvik.cz/link/bmc22025347

Online Plný text

NLK ProQuest Central od 1997-02-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Nursing & Allied Health Database (ProQuest) od 1997-02-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-02-01 do Před 1 rokem

PubMed 35614319
DOI 10.1038/s41375-022-01607-z
Knihovny.cz E-zdroje

MeSH
bcr-abl fúzní proteiny genetika MeSH
chronická myeloidní leukemie * diagnóza genetika MeSH
lidé MeSH
referenční standardy MeSH
syndrom chronické únavy * MeSH
výsledek terapie MeSH
Check Tag
lidé MeSH
Publikační typ
časopisecké články MeSH
práce podpořená grantem MeSH

Standardized monitoring of BCR::ABL1 mRNA levels is essential for the management of chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and Outcome Study for CML (EUTOS) explored the use of secondary, lyophilized cell-based BCR::ABL1 reference panels traceable to the World Health Organization primary reference material to standardize and validate local laboratory tests. Panels were used to assign and validate conversion factors (CFs) to the International Scale and assess the ability of laboratories to assess deep molecular response (DMR). The study also explored aspects of internal quality control. The percentage of EUTOS reference laboratories (n = 50) with CFs validated as optimal or satisfactory increased from 67.5% to 97.6% and 36.4% to 91.7% for ABL1 and GUSB, respectively, during the study period and 98% of laboratories were able to detect MR4.5 in most samples. Laboratories with unvalidated CFs had a higher coefficient of variation for BCR::ABL1IS and some laboratories had a limit of blank greater than zero which could affect the accurate reporting of DMR. Our study indicates that secondary reference panels can be used effectively to obtain and validate CFs in a manner equivalent to sample exchange and can also be used to monitor additional aspects of quality assurance.

2nd Medical Department University Hospital Schleswig Holstein Campus Kiel Germany

3 Medizinische Klinik Universitätsmedizin Mannheim Mannheim Germany

Abteilung Hämatologie Onkologie Klinik für Innere Medizin 2 Universitätsklinikum Jena Jena Germany

Amsterdam University Medical Center Amsterdam The Netherlands

Cancer Molecular Diagnostics St James's Hospital Dublin Ireland

Centro de Investigación Biomédica en Red de Cáncer Instituto Carlos 3 28029 Madrid Spain

CHU Lille Laboratoire d'hématologie F 59000 Lille France

Clinical Genetics Karolinska University Hospital Stockholm Sweden

Department of Clinical and Experimental Medicine Center of Experimental Oncology and Hematology University of Catania Catania Italy

Department of Emergency and Organ Transplantation Hematology and Stem Cell Transplantation Unit University of Bari Aldo Moro Bari Italy

Department of Genetics and Research Centre Portuguese Oncology Institute of Porto Porto Portugal

Department of Genomics Turku University Hospital Laboratories Turku Finland

Department of Haematology University Medical Centre Ljubljana Ljubljana Slovenia

Department of Immunology Genetics and Pathology Uppsala University Uppsala Sweden

Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic

Department of Medical Genetics National Cancer Institute Bratislava Slovakia

Department of Medical Oncology and Hematology University Hospital Zurich University of Zurich Zurich Switzerland

Department of Molecular Hemato Oncology LHUB ULB Brussels Belgium

Department of Molecular Medicine and Medical Biotechnology University 'Federico II' and CEINGE Advanced Biotechnologies Naples Italy

Department of Pathology Zealand University Hospital Roskilde Denmark

Faculty of Medicine Masaryk University Brno Czech Republic

Faculty of Medicine University of Southampton Southampton UK

Faculty of Pharmacy University of Ljubljana Ljubljana Slovenia

Fundeni Clinical Institute Hematology Department Bucharest Romania

Haematological Malignancy Diagnostic Service Leeds Teaching Hospitals Leeds UK

Haematology Research Laboratory National and Kapodistrian University of Athens School of Medicine Athens Greece

Hematological Malignancies Clinical Research Unit CNIO 28029 Madrid Spain

Hematology Department Faculty of Medicine University of Medicine and Pharmacy Carol Davila Bucharest Romania

Hematology Department Hospital Regional Universitario de Málaga IBIMA Málaga Spain

Hematology Department Hospital Universitario 12 de Octubre Instituto de Investigación Sanitaria Imas12 28041 Madrid Spain

Hematology Department Hospital Universitario de Gran Canaria Doctor Negrín Las Palmas de Gran Canaria Las Palmas Spain

HemoDiagnostic Laboratory Department of Hematology Aarhus University Hospital Aarhus Denmark

Hospices Civils de Lyon Hôpital Lyon Sud Service d'Hématologie Biologique Pierre Bénite France

Institute for Hematology and Oncology Mannheim Germany

Institute of Hematology and Blood Transfusion Prague Czech Republic

IRCSS Azienda Ospedaliero Universitaria di Bologna Istituto di Ematologia Seràgnoli Bologna Italy

Labdia Labordiagnostik St Anna Children ́s Cancer Research Institute Vienna Austria

Laboratório de Hemato Oncologia LHO Instituto Português de Oncologia Francisco Gentil Lisbon Portugal

Laboratory of Chemical and Clinical Analysis Area 3 A O U San Luigi Gonzaga Orbassano Turin Italy

Laboratory of Hematology University Hospital Saint Louis Université de Paris Paris France

Laboratory of Medical Genetics National Specialized Hospital for Active Treatment of Hematological Diseases Sofia Bulgaria

Laboratory of Molecular Genetics Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases Budapest Hungary

Medical University of Vienna Department of Laboratory Medicine Vienna Austria

MLL Munich Leukemia Laboratory Munich Germany

Molecular Diagnostics Laboratory Hematology Department and HCT Unit George Papanicolaou General Hospital Thessaloniki Greece

Molecular Hemapathology Oslo University Hospital Oslo Norway

Pathology Department Hospital Clinic Institut d' Investigacions Biomèdiques August Pi i Sunyer CIBERONC Barcelona Spain

Pathology Department University Clinical Center Tuzla Policlinic for Laboratory Diagnostics Tuzla Bosnia and Herzegovina

Poznan University of Medical Sciences Department of Hematology and Bone Marrow Transplantation Poznan Poland

Ritus Biotec Laboratory Codlea Brasov Romania

Section of Molecular Diagnostics Clinical Genetics Region Skåne Lund Sweden

SIHMDS Hosted by Imperial College Healthcare NHS Trust at Hammersmith Hospital London UK

The University Hospital in Krakow Krakow Poland

Transilvania University Brasov Romania

University Hospital Bern Bern Switzerland

University Hospital Center Zagreb Zagreb Croatia

University Hospital of Bordeaux Laboratory of Hematology Haut Lévêque Hospital Pessac France

University of Bern Bern Switzerland

University of Leipzig Medical Center Department for Hematology Cellular Therapies and Hemostaseology Leipzig Germany

Vilnius University Hospital Santaros Klinikos Vilnius Lithuania

Wessex Regional Genetics Laboratory Salisbury NHS Foundation Trust Salisbury UK

West Midlands Regional Genetics Laboratory Birmingham Women's and Children's NHS Foundation Trust Birmingham UK

Citace poskytuje Crossref.org

000: 00000naa a2200000 a 4500

001: bmc22025347

003: CZ-PrNML

005: 20221031100155.0

007: ta

008: 221017s2022 enk f 000 0|eng||

009: AR

024 7_: $a 10.1038/s41375-022-01607-z $2 doi

035 __: $a (PubMed)35614319

040 __: $a ABA008 $b cze $d ABA008 $e AACR2

041 0_: $a eng

044 __: $a enk

100 1_: $a White, Helen E $u Faculty of Medicine, University of Southampton, Southampton, UK $u Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, UK

245 10: $a Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study / $c HE. White, M. Salmon, F. Albano, CSA. Andersen, S. Balabanov, G. Balatzenko, G. Barbany, JM. Cayuela, N. Cerveira, P. Cochaux, D. Colomer, D. Coriu, J. Diamond, C. Dietz, S. Dulucq, M. Engvall, GN. Franke, E. Gineikiene-Valentine, M. Gniot, MT. Gómez-Casares, E. Gottardi, C. Hayden, S. Hayette, A. Hedblom, A. Ilea, B. Izzo, A. Jiménez-Velasco, T. Jurcek, V. Kairisto, SE. Langabeer, T. Lion, N. Meggyesi, S. Mešanović, L. Mihok, G. Mitterbauer-Hohendanner, S. Moeckel, N. Naumann, O. Nibourel, E. Oppliger Leibundgut, P. Panayiotidis, H. Podgornik, C. Pott, I. Rapado, SJ. Rose, V. Schäfer, T. Touloumenidou, C. Veigaard, B. Venniker-Punt, C. Venturi, P. Vigneri, I. Vorkinn, E. Wilkinson, R. Zadro, M. Zawada, H. Zizkova, MC. Müller, S. Saussele, T. Ernst, K. Machova Polakova, A. Hochhaus, NCP. Cross

520 9_: $a Standardized monitoring of BCR::ABL1 mRNA levels is essential for the management of chronic myeloid leukemia (CML) patients. From 2016 to 2021 the European Treatment and Outcome Study for CML (EUTOS) explored the use of secondary, lyophilized cell-based BCR::ABL1 reference panels traceable to the World Health Organization primary reference material to standardize and validate local laboratory tests. Panels were used to assign and validate conversion factors (CFs) to the International Scale and assess the ability of laboratories to assess deep molecular response (DMR). The study also explored aspects of internal quality control. The percentage of EUTOS reference laboratories (n = 50) with CFs validated as optimal or satisfactory increased from 67.5% to 97.6% and 36.4% to 91.7% for ABL1 and GUSB, respectively, during the study period and 98% of laboratories were able to detect MR4.5 in most samples. Laboratories with unvalidated CFs had a higher coefficient of variation for BCR::ABL1IS and some laboratories had a limit of blank greater than zero which could affect the accurate reporting of DMR. Our study indicates that secondary reference panels can be used effectively to obtain and validate CFs in a manner equivalent to sample exchange and can also be used to monitor additional aspects of quality assurance.

650 12: $a syndrom chronické únavy $7 D015673

650 _2: $a bcr-abl fúzní proteiny $x genetika $7 D016044

650 _2: $a lidé $7 D006801

650 12: $a chronická myeloidní leukemie $x diagnóza $x genetika $7 D015464

650 _2: $a referenční standardy $7 D012015

650 _2: $a výsledek terapie $7 D016896

655 _2: $a časopisecké články $7 D016428

655 _2: $a práce podpořená grantem $7 D013485

700 1_: $a Salmon, Matthew $u Faculty of Medicine, University of Southampton, Southampton, UK $u Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, UK

700 1_: $a Albano, Francesco $u Department of Emergency and Organ Transplantation (D.E.T.O.)-Hematology and Stem Cell Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy $1 https://orcid.org/http://orcid.org/0000000179266052

700 1_: $a Andersen, Christina Søs Auður $u Department of Pathology, Zealand University Hospital, Roskilde, Denmark

700 1_: $a Balabanov, Stefan $u Department of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

700 1_: $a Balatzenko, Gueorgui $u Laboratory of Medical Genetics National Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria

700 1_: $a Barbany, Gisela $u Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden

700 1_: $a Cayuela, Jean-Michel $u Laboratory of Hematology, University Hospital Saint-Louis, Université de Paris, Paris, France

700 1_: $a Cerveira, Nuno $u Department of Genetics and Research Centre, Portuguese Oncology Institute of Porto, Porto, Portugal

700 1_: $a Cochaux, Pascale $u Department of Molecular Hemato-Oncology, LHUB-ULB, Brussels, Belgium

700 1_: $a Colomer, Dolors $u Pathology Department, Hospital Clinic, Institut d' Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona, Spain $1 https://orcid.org/http://orcid.org/0000000174868484

700 1_: $a Coriu, Daniel $u Fundeni Clinical Institute, Hematology Department, Bucharest, Romania $u Hematology Department, Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania

700 1_: $a Diamond, Joana $u Laboratório de Hemato-Oncologia-LHO Instituto Português de Oncologia Francisco Gentil, Lisbon, Portugal $1 https://orcid.org/http://orcid.org/0000000279715900

700 1_: $a Dietz, Christian $u Institute for Hematology and Oncology (IHO GmbH), Mannheim, Germany

700 1_: $a Dulucq, Stéphanie $u University Hospital of Bordeaux, Laboratory of Hematology, Haut Lévêque Hospital, Pessac, France $1 https://orcid.org/http://orcid.org/0000000327287243

700 1_: $a Engvall, Marie $u Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

700 1_: $a Franke, Georg N $u University of Leipzig Medical Center, Department for Hematology, Cellular Therapies and Hemostaseology, Leipzig, Germany

700 1_: $a Gineikiene-Valentine, Egle $u Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania

700 1_: $a Gniot, Michal $u Poznan University of Medical Sciences, Department of Hematology and Bone Marrow Transplantation, Poznan, Poland $1 https://orcid.org/http://orcid.org/0000000275353316

700 1_: $a Gómez-Casares, María Teresa $u Hematology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas, Spain

700 1_: $a Gottardi, Enrico $u Laboratory of Chemical and Clinical Analysis "Area 3" A.O.U San Luigi Gonzaga-Orbassano, Turin, Italy

700 1_: $a Hayden, Chloe $u SIHMDS Hosted by Imperial College Healthcare NHS Trust at Hammersmith Hospital, London, UK

700 1_: $a Hayette, Sandrine $u Hospices Civils de Lyon, Hôpital Lyon Sud, Service d'Hématologie Biologique, Pierre-Bénite, France

700 1_: $a Hedblom, Andreas $u Section of Molecular Diagnostics, Clinical Genetics, Region Skåne, Lund, Sweden

700 1_: $a Ilea, Anca $u Ritus Biotec Laboratory, Codlea-Brasov, Romania $u Transilvania University, Brasov, Romania

700 1_: $a Izzo, Barbara $u Department of Molecular Medicine and Medical Biotechnology University 'Federico II' and CEINGE-Advanced Biotechnologies, Naples, Italy $1 https://orcid.org/http://orcid.org/0000000270210367

700 1_: $a Jiménez-Velasco, Antonio $u Hematology Department, Hospital Regional Universitario de Málaga, IBIMA, Málaga, Spain

700 1_: $a Jurcek, Tomas $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic

700 1_: $a Kairisto, Veli $u Department of Genomics, Turku University Hospital Laboratories, Turku, Finland

700 1_: $a Langabeer, Stephen E $u Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland

700 1_: $a Lion, Thomas $u Labdia Labordiagnostik/St. Anna Children ́s Cancer Research Institute (CCRI), Vienna, Austria

700 1_: $a Meggyesi, Nora $u Laboratory of Molecular Genetics, Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, Budapest, Hungary

700 1_: $a Mešanović, Semir $u Pathology Department, University Clinical Center Tuzla, Policlinic for Laboratory Diagnostics, Tuzla, Bosnia and Herzegovina

700 1_: $a Mihok, Luboslav $u Department of Medical Genetics, National Cancer Institute, Bratislava, Slovakia

700 1_: $a Mitterbauer-Hohendanner, Gerlinde $u Medical University of Vienna, Department of Laboratory Medicine, Vienna, Austria

700 1_: $a Moeckel, Sylvia $u MLL Munich Leukemia Laboratory, Munich, Germany

700 1_: $a Naumann, Nicole $u III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany

700 1_: $a Nibourel, Olivier $u CHU Lille, Laboratoire d'hématologie, F-59000, Lille, France

700 1_: $a Oppliger Leibundgut, Elisabeth $u University Hospital Bern, Bern, Switzerland $u University of Bern, Bern, Switzerland

700 1_: $a Panayiotidis, Panayiotis $u Haematology Research Laboratory, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

700 1_: $a Podgornik, Helena $u Department of Haematology, University Medical Centre Ljubljana, Ljubljana, Slovenia $u Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia

700 1_: $a Pott, Christiane $u Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Germany

700 1_: $a Rapado, Inmaculada $u Hematology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Imas12, 28041, Madrid, Spain $u Hematological Malignancies Clinical Research Unit, CNIO, 28029, Madrid, Spain $u Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Carlos III, 28029, Madrid, Spain

700 1_: $a Rose, Susan J $u West Midlands Regional Genetics Laboratory, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK

700 1_: $a Schäfer, Vivien $u Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany

700 1_: $a Touloumenidou, Tasoula $u Molecular Diagnostics Laboratory, Hematology Department and HCT Unit, George Papanicolaou General Hospital, Thessaloniki, Greece

700 1_: $a Veigaard, Christopher $u HemoDiagnostic Laboratory, Department of Hematology, Aarhus University Hospital, Aarhus, Denmark

700 1_: $a Venniker-Punt, Bianca $u Amsterdam University Medical Center, Amsterdam, The Netherlands

700 1_: $a Venturi, Claudia $u IRCSS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli", Bologna, Italy

700 1_: $a Vigneri, Paolo $u Department of Clinical and Experimental Medicine, Center of Experimental Oncology and Hematology, University of Catania, Catania, Italy

700 1_: $a Vorkinn, Ingvild $u Molecular Hemapathology, Oslo University Hospital, Oslo, Norway

700 1_: $a Wilkinson, Elizabeth $u Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals, Leeds, UK

700 1_: $a Zadro, Renata $u University Hospital Center Zagreb, Zagreb, Croatia

700 1_: $a Zawada, Magdalena $u The University Hospital in Krakow, Krakow, Poland

700 1_: $a Zizkova, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic

700 1_: $a Müller, Martin C $u Institute for Hematology and Oncology (IHO GmbH), Mannheim, Germany

700 1_: $a Saussele, Susanne $u III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany $1 https://orcid.org/http://orcid.org/0000000303575785

700 1_: $a Ernst, Thomas $u Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany $1 https://orcid.org/http://orcid.org/000000032147489X

700 1_: $a Machova Polakova, Katerina $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/http://orcid.org/0000000273985555

700 1_: $a Hochhaus, Andreas $u Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany $1 https://orcid.org/http://orcid.org/0000000306260834

700 1_: $a Cross, Nicholas C P $u Faculty of Medicine, University of Southampton, Southampton, UK. ncpc@soton.ac.uk $u Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, UK. ncpc@soton.ac.uk $1 https://orcid.org/http://orcid.org/0000000154812555

773 0_: $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 36, č. 7 (2022), s. 1834-1842

856 41: $u https://pubmed.ncbi.nlm.nih.gov/35614319 $y Pubmed

910 __: $a ABA008 $b sig $c sign $y p $z 0

990 __: $a 20221017 $b ABA008

991 __: $a 20221031100153 $b ABA008

999 __: $a ok $b bmc $g 1854855 $s 1176637

BAS __: $a 3

BAS __: $a PreBMC

BMC __: $a 2022 $b 36 $c 7 $d 1834-1842 $e 20220525 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138

LZP __: $a Pubmed-20221017

Zpět

Najít záznam

v PubMed

Citační ukazatele

Pouze přihlášení uživatelé

Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study

Najít záznam

Citační ukazatele

Možnosti archivace